Full Press Release Details
The datasets to be reported at the ASCO Annual Meeting include:
The accepted abstracts are listed below, and abstract titles are available today on the ASCO conference website: meetings.asco.org .
Data Presentations
Poster Presentation Title : BLU-222, an oral, potent and selective CDK2 inhibitor, in patients with advanced solid tumors: phase 1 monotherapy dose escalation Session Title : Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Session Date & Time : Saturday, June 3, 2023 from 8:00 a.m. — 11:00 a.m. CT ( 9:00 a.m. — 12:00 p.m. ET ) Abstract Number : 3095 Location : Hall A
Poster Presentation Title : Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions Session Title : Lung Cancer—Non-Small Cell Metastatic Session Date & Time : Sunday, June 4, 2023 from 8:00 a.m. — 11:00 a.m. CT ( 9:00 a.m. — 12:00 p.m. ET ) Abstract Number : 9064 Location : Hall A
Short Oral Presentation Title : BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study Session Title : Rapid Abstract Session: Lung Cancer Session Date & Time : Monday, June 5, 2023 from 11:30 a.m. — 12:30 p.m. CT ( 12:30 p.m. — 1:30 p.m. ET ) Abstract Number : 9011 Location : S406
About Blueprint Medicines
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidates, including the results of ongoing clinical trials; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' financial performance, growth strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the COVID-19 pandemic may impact Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including ongoing and planned research and discovery activities, Blueprint Medicines' ability to conduct ongoing and planned clinical trials; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect the initiation, timing and progress of clinical trials; risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; and the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.
Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.
SOURCE Blueprint Medicines Corporation